DK1749836T3 - Rekombinant vaskulær endothelcellevækstfaktor D - Google Patents

Rekombinant vaskulær endothelcellevækstfaktor D

Info

Publication number: DK1749836T3
Authority: DK; Denmark
Prior art keywords: endothelial cell; growth factor; cell growth; vascular endothelial; recombinant vascular
Prior art date: 1996-08-23

Application number

DK06121918T

Other languages

English (en)

Inventor

Marc G Achen

Andrew F Wilks

Steven A Stacker

Kari Alitalo

Original Assignee

Vegenics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-23

Filing date

1997-08-21

Publication date

2009-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46149776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1749836(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-08-23 Priority claimed from AUPO1825A external-priority patent/AUPO182596A0/en

1996-11-11 Priority claimed from AUPO3554A external-priority patent/AUPO355496A0/en

1997-02-05 Priority claimed from AUPO4954A external-priority patent/AUPO495497A0/en

1997-06-19 Priority claimed from AUPO7435A external-priority patent/AUPO743597A0/en

1997-08-21 Application filed by Vegenics Ltd filed Critical Vegenics Ltd

2009-08-31 Application granted granted Critical

2009-08-31 Publication of DK1749836T3 publication Critical patent/DK1749836T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK06121918T 1996-08-23 1997-08-21 Rekombinant vaskulær endothelcellevækstfaktor D DK1749836T3 (da)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US2375196P	1996-08-23	1996-08-23
AUPO1825A AUPO182596A0 (en)	1996-08-23	1996-08-23	Growth factor
AUPO3554A AUPO355496A0 (en)	1996-11-11	1996-11-11	Growth factor
US3109796P	1996-11-14	1996-11-14
AUPO4954A AUPO495497A0 (en)	1997-02-05	1997-02-05	Growth factors
US3881497P	1997-02-10	1997-02-10
AUPO7435A AUPO743597A0 (en)	1997-06-19	1997-06-19	Growth factor
US5142697P	1997-07-01	1997-07-01
PCT/US1997/014696 WO1998007832A1 (en)	1996-08-23	1997-08-21	Recombinant vascular endothelial cell growth factor d (vegf-d)

Publications (1)

Publication Number	Publication Date
DK1749836T3 true DK1749836T3 (da)	2009-08-31

Family

ID=46149776

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK97938486T DK0956339T3 (da)	1996-08-23	1997-08-21	Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
DK09162873.5T DK2107109T3 (da)	1996-08-23	1997-08-21	Rekombinant vaskulær endotelcelle-vækstfaktor D (VEGF-D)
DK06121918T DK1749836T3 (da)	1996-08-23	1997-08-21	Rekombinant vaskulær endothelcellevækstfaktor D

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK97938486T DK0956339T3 (da)	1996-08-23	1997-08-21	Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
DK09162873.5T DK2107109T3 (da)	1996-08-23	1997-08-21	Rekombinant vaskulær endotelcelle-vækstfaktor D (VEGF-D)

Country Status (10)

Country	Link
US (14)	US6235713B1 (da)
EP (4)	EP2107109B1 (da)
JP (3)	JP2001517075A (da)
AT (2)	ATE434034T1 (da)
AU (1)	AU729880C (da)
CA (1)	CA2263890C (da)
DE (2)	DE69739469D1 (da)
DK (3)	DK0956339T3 (da)
ES (3)	ES2390107T3 (da)
WO (1)	WO1998007832A1 (da)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6824777B1 (en)	1992-10-09	2004-11-30	Licentia Ltd.	Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7186688B1 (en)	1994-03-08	2007-03-06	Human Genome Sciences, Inc.	Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US7109308B1 (en)	1994-03-08	2006-09-19	Human Genome Sciences, Inc.	Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en)	1994-03-08	2006-12-26	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 and methods of use
US6734285B2 (en)	1994-03-08	2004-05-11	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 proteins and compositions
US6040157A (en)	1994-03-08	2000-03-21	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
AU696764B2 (en)	1994-03-08	1998-09-17	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US5932540A (en)	1994-03-08	1999-08-03	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US7597886B2 (en)	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US7423125B2 (en)	1995-08-01	2008-09-09	Vegenics Limited	Antibodies to VEGF-C
AU710696C (en)	1995-09-08	2002-10-24	Genentech Inc.	VEGF-related protein
EP0853668B2 (en)	1995-09-29	2013-03-06	Vegenics Pty Ltd	Regulated genes and uses thereof
US7357927B2 (en)	1996-03-12	2008-04-15	Human Genome Sciences, Inc.	Death domain containing receptors
WO1997033904A1 (en)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Death domain containing receptors
US6713061B1 (en)	1996-03-12	2004-03-30	Human Genome Sciences, Inc.	Death domain containing receptors
US6635743B1 (en)	1996-03-22	2003-10-21	Human Genome Sciences, Inc.	Apoptosis inducing molecule II and methods of use
US7964190B2 (en)	1996-03-22	2011-06-21	Human Genome Sciences, Inc.	Methods and compositions for decreasing T-cell activity
EP0935001B2 (en) *	1996-07-15	2011-08-10	Chugai Seiyaku Kabushiki Kaisha	Novel vegf-like factors
DK0956339T3 (da) *	1996-08-23	2006-01-30	Licentia Oy	Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
US7125714B2 (en)	1997-02-05	2006-10-24	Licentia Ltd.	Progenitor cell materials and methods
US20020137890A1 (en) *	1997-03-31	2002-09-26	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6391311B1 (en)	1998-03-17	2002-05-21	Genentech, Inc.	Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US7947472B2 (en) *	1997-12-24	2011-05-24	Vegenics Limited	Expression vectors and cell lines expressing vascular endothelial growth factor D
AU765888B2 (en) *	1997-12-24	2003-10-02	Vegenics Limited	Expression vectors and cell lines expressing vascular endothelial growth factor D, and method of treating melanomas
EP1064382B1 (en)	1998-03-17	2008-08-20	Genentech, Inc.	Polypeptides homologous to vegf and bmp1
EP0984063A3 (en) *	1998-08-31	2000-08-16	Eli Lilly And Company	VEGF Related gene and protein
US20040053837A1 (en) *	1998-09-30	2004-03-18	Ludwig Institute For Cancer Research	Composition and method for modulating vasculogenesis or angiogenesis
US20030082670A1 (en) *	1998-09-30	2003-05-01	Ulf Eriksson	Platelet-derived growth factor C, DNA coding therefor, and uses thereof
US20030211994A1 (en) *	1998-09-30	2003-11-13	Ludwig Institute For Cancer Research	Composition and method for modulating vasculogenesis or angiogenesis
CN100340291C (zh)	1998-10-09	2007-10-03	路德维格癌症研究院	F1t4(VEGFR－3)作为肿瘤显像和抗肿瘤治疗的靶
US6958147B1 (en)	1998-10-26	2005-10-25	Licentia Ltd	Use of VEGF-C to prevent restenosis
EP1568375A1 (en) *	1998-10-26	2005-08-31	Ludwig Institute For Cancer Research	Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
ES2229788T3 (es) *	1998-10-26	2005-04-16	Ludwig Institute For Cancer Research	Uso del gen o proteina vegf-c o vegf-d para prevenir la restenosis.
DK1129110T3 (da)	1998-11-10	2010-04-06	Ludwig Inst Cancer Res	Blodpladeafledt vækstfaktor D, DNA kodende derfor og anvendelser deraf
ES2432053T3 (es) *	1998-12-07	2013-11-29	Zymogenetics, Inc.	Homólogo del factor del crecimiento ZVEGF3
ATE322909T1 (de) *	1998-12-21	2006-04-15	Ludwig Inst Cancer Res	Antikörper gegen verkürzten vegf-d und deren verwendungen
US6783953B1 (en)	1998-12-22	2004-08-31	Janssen Pharmaceutica N.V.	Vascular endothelial growth factor-X
DK1141293T3 (da) *	1998-12-22	2007-11-12	Janssen Pharmaceutica Nv	Vaskulær endotelial vækstfaktor-X
US7223724B1 (en)	1999-02-08	2007-05-29	Human Genome Sciences, Inc.	Use of vascular endothelial growth factor to treat photoreceptor cells
CA2363779A1 (en)	1999-02-26	2000-08-31	Human Genome Sciences, Inc.	Human endokine alpha and methods of use
US6764820B2 (en)	1999-03-26	2004-07-20	Ludwig Institute For Cancer Research	Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
WO2000058511A1 (en)	1999-03-26	2000-10-05	Ludwig Institute For Cancer Research	Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
ES2199804T3 (es) *	1999-03-26	2004-03-01	Regeneron Pharmaceuticals, Inc.	Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
US6372494B1 (en)	1999-05-14	2002-04-16	Advanced Tissue Sciences, Inc.	Methods of making conditioned cell culture medium compositions
CA2381985A1 (en) *	1999-08-16	2001-02-22	Universita'degli Studi Di Siena	Vegf-d and angiogenic use thereof
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
EP1248642A4 (en) *	2000-01-18	2005-05-18	Ludwig Inst Cancer Res	PEPTIDOMIMETIC INHIBITOR OF VEGF-D / VEGF-C / VEGF
AU4643501A (en) *	2000-02-04	2001-08-14	Flanders Interuniversity Institute For Biotechnology (Vib)	Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
US7105168B1 (en)	2002-06-04	2006-09-12	D. Collen Research Foundation Vzw	Method of improving ischemic muscle function by administering placental growth factor
US7727971B2 (en)	2000-02-04	2010-06-01	Life Sciences Research Partners Vzw	Use of placental growth factor for treating ischemic muscle disease
US6930089B2 (en)	2000-02-04	2005-08-16	D. Collen Research Foundation Vzw	Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
SK12712002A3 (sk)	2000-02-07	2003-02-04	Abbott Gmbh & Co. Kg	Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
WO2001062942A2 (en) *	2000-02-25	2001-08-30	Ludwig Institute For Cancer Research	MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS
WO2001064235A1 (en) *	2000-03-02	2001-09-07	Ludwig Institute For Cancer Research	Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
US20020102260A1 (en) *	2000-03-02	2002-08-01	Marc Achen	Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
DK1259248T3 (da) *	2000-03-02	2005-04-11	Ludwig Inst Cancer Res	Fremgangsmåde til behandling af cancere, der udtrykker vaskulær endotelvækstfaktor D
AU2006201128B2 (en) *	2000-03-02	2009-05-28	Vegenics Limited	Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D
EP2067488A1 (en)	2000-04-12	2009-06-10	Human Genome Sciences, Inc.	Albumin fusion proteins
AU6456501A (en) *	2000-05-03	2001-11-12	Ludwig Inst Cancer Res	A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
US7273751B2 (en)	2000-08-04	2007-09-25	Human Genome Science, Inc.	Vascular endothelial growth factor-2
JP2004527462A (ja) *	2000-11-01	2004-09-09	ルードヴィッヒインスティテュートフォーキャンサーリサーチ	血管新生活性のｉｎｖｉｖｏ刺激
JP2004537260A (ja)	2000-12-07	2004-12-16	サンガモバイオサイエンシーズ，インコーポレイテッド	ジンクフィンガータンパク質による血管新生の調節
US7067317B2 (en)	2000-12-07	2006-06-27	Sangamo Biosciences, Inc.	Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) *	2001-01-17	2009-11-03	Vegenics Limited	VEGFR-3 inhibitor materials and methods
CA2435503C (en)	2001-01-19	2011-02-22	Ludwig Institute For Cancer Research	Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
WO2002064097A2 (en) *	2001-02-12	2002-08-22	The Penn State Research Foundation	Vegf-d expression in brain cancer
MXPA03008560A (es)	2001-03-22	2004-06-30	Abbot Gmbh & Co Kg	Pirazolopirimidinas como agentes terapeuticos.
US7402312B2 (en)	2001-04-13	2008-07-22	Human Genome Sciences, Inc.	Antibodies to vascular endothelial growth factor 2 (VEGF-2)
ATE470676T1 (de)	2001-04-13	2010-06-15	Human Genome Sciences Inc	Anti-vegf-2 antikörper
AU2002345603B2 (en) *	2001-06-07	2006-10-12	Skinmedica, Inc.	Conditioned cell culture media and uses thereof
CA2453161A1 (en) *	2001-07-12	2003-01-23	Ludwig Institute For Cancer Research	Lymphatic endothelial cells materials and methods
WO2003013570A1 (en) *	2001-08-09	2003-02-20	Cornell Research Foundation, Inc.	Platelet-derived growth factor protection of cardiac myocardium
US20030113324A1 (en)	2001-10-01	2003-06-19	Kari Alitalo	Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) *	2001-10-01	2004-10-28	Kari Alitalo	VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
HUP0402332A3 (en)	2001-10-15	2009-07-28	Janssen Pharmaceutica Nv	Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage and pharmaceutical compositions containing them
CA2471363C (en)	2001-12-21	2014-02-11	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2478063A1 (en) *	2002-03-07	2003-10-02	Ludwig Institute For Cancer Research	Lymphatic and blood endothelial cell genes
US7241446B2 (en) *	2002-04-01	2007-07-10	Trustees Of Dartmouth College	Methods for modulating angiogenesis via VEGF
US7510714B2 (en) *	2002-04-01	2009-03-31	Trustees Of Dartmouth College	Methods for modulating angiogenesis
AU2003228762A1 (en) *	2002-05-03	2003-11-17	Ludwig Institute For Cancer Research	Preventing secondary lymphedema with vegf-d dna
US7563882B2 (en)	2002-06-10	2009-07-21	University Of Rochester	Polynucleotides encoding antibodies that bind to the C35 polypeptide
CN1684706A (zh)	2002-07-23	2005-10-19	路德维格癌症研究所	活化或抑制vegf－d和vegf－c的方法和组合物
US20040120950A1 (en) *	2002-12-20	2004-06-24	Kari Alitalo	Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
WO2004070018A2 (en) *	2003-02-04	2004-08-19	Ludwig Institute For Cancer Research	Vegf-b and pdgf modulation of stem cells
WO2005016963A2 (en) *	2003-06-12	2005-02-24	Ludwig Institute For Cancer Research	Heparin binding veger-3 ligands
EP1635860A2 (en) *	2003-06-12	2006-03-22	Ludwig Institute For Cancer Research	Use of vegf-c or vegf-d in reconstructive surgery
WO2005026362A2 (en) *	2003-09-08	2005-03-24	Ludwig Institute For Cancer Reserach	Lymphatic and blood endothelial cell genes
US7284505B1 (en)	2003-11-03	2007-10-23	Paxton Stephen E	Skijor system
US7780973B2 (en) *	2003-12-15	2010-08-24	Ethicon Endo-Surgery, Inc.	Method and device for minimally invasive implantation of biomaterial
CA2550727A1 (en) *	2003-12-29	2005-07-14	Centelion	Treatment of coronary or peripheral ischemia
US20050142161A1 (en) *	2003-12-30	2005-06-30	Freeman Lynetta J.	Collagen matrix for soft tissue augmentation
WO2005087177A2 (en) *	2004-03-05	2005-09-22	Ludwig Institute For Cancer Research	Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
WO2005087812A1 (en) *	2004-03-05	2005-09-22	Ludwig Institute For Cancer Research	Multivalent antibody materials and methods for vegf/pdgf family of growth factors
EP1725678A1 (en) *	2004-03-12	2006-11-29	Ludwig Institute For Cancer Research	Differential drug sensitivity
US7595149B1 (en)	2004-11-08	2009-09-29	University Of Kentucky Research Foundation	Methods for cancer detection
EP1869075B1 (en)	2005-02-28	2012-04-11	Sangamo BioSciences, Inc.	Anti-angiogenic methods and compositions
DE602006020881D1 (de)	2005-08-15	2011-05-05	Vegenics Pty Ltd	Enen eigenschaften
TW200732347A (en) *	2005-10-06	2007-09-01	Trophogen Inc	VEGF analogs and methods of use
ES2396440T3 (es)	2006-01-18	2013-02-21	The General Hospital Corporation	Métodos de aumentar la función linfática
DK2018184T3 (da)	2006-05-17	2013-10-28	Ludwig Inst Cancer Res	Anti-vegf-b-antistof til behandling eller forebyggende behandling af type 2-diabetes eller metabolisk syndrom
WO2008093246A2 (en)	2007-02-02	2008-08-07	Vegenics Limited	Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
WO2008096268A2 (en) *	2007-02-07	2008-08-14	Vegenics Limited	Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
US7811776B2 (en)	2007-12-05	2010-10-12	University Of Cincinnati	Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease
WO2009082485A1 (en)	2007-12-26	2009-07-02	Vaccinex, Inc.	Anti-c35 antibody combination therapies and methods
WO2009143584A1 (en) *	2008-05-30	2009-12-03	Vegenics Limited	Treatment of pulmonary edema
US20100029491A1 (en) *	2008-07-11	2010-02-04	Maike Schmidt	Methods and compositions for diagnostic use for tumor treatment
US8255807B2 (en) *	2008-12-23	2012-08-28	Ganz	Item customization and website customization
US20120093811A1 (en) *	2009-04-03	2012-04-19	Simmonds Jason W	Anti-vegf-d antibodies
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
EP2538965B1 (en)	2010-02-25	2017-04-12	Schepens Eye Research Institute	Therapeutic compositions for the treatment of dry eye disease
WO2011154308A1 (en)	2010-06-08	2011-12-15	Proyecto De Biomedicina Cima, S.L.	New compositions and cell therapy methods for the treatment of cirrhosis
WO2012088563A1 (en) *	2010-11-24	2012-07-05	Vegenics Pty Limited	Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
WO2012154983A2 (en)	2011-05-10	2012-11-15	Biocare Medical, Llc	Systems and methods for anti-pax8 antibodies
US9415090B2 (en) *	2011-06-01	2016-08-16	Universität Heidelberg	VEGF-D/VEGFR2/3-mediated regulation of dendrites
US10316103B1 (en)	2012-03-30	2019-06-11	Biocare Medical, Llc	Systems and methods for anti-Uroplakin III antibodies
US10457713B2 (en)	2012-07-30	2019-10-29	Trophogen, Inc.	Glycoprotein hormone long-acting superagonists
NZ707016A (en)	2012-07-30	2017-08-25	Trophogen Inc	Glycoprotein hormone long-acting superagonists
EP2900265B1 (en)	2012-09-27	2018-05-30	Biocare Medical, LLC	Anti-uroplakin ii antibodies systems and methods
WO2014100220A2 (en)	2012-12-18	2014-06-26	Biocare Medical, Llc	Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
MY170528A (en)	2013-02-18	2019-08-09	Vegenics Pty Ltd	Vegfr-3 ligand binding molecules and uses thereof
DK2962113T3 (da)	2013-02-28	2019-07-01	Biocare Medical Llc	Systemer og fremgangsmåder med anti-p40-antistoffer
JP6506267B2 (ja)	2013-10-03	2019-04-24	バイオケアメディカル，エルエルシー	抗ｓｏｘ１０抗体のシステムおよび方法
RU2016117119A (ru)	2013-11-05	2017-12-11	Трофоген Инк.	Пролонгированного действия суперагонисты гликопротеинового гормона
EP3924367A4 (en) *	2019-04-04	2022-10-12	Sree Chitra Tirunal Institute for Medical Sciences and Technology	VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) FOR BETTER WOUND HEALING THROUGH ENHANCED ANGIOGENESIS
CA3213051A1 (en) *	2021-03-10	2022-09-15	Sumitomo Pharma Co., Ltd.	Method for producing cysteine knot protein
WO2024259161A2 (en) *	2023-06-14	2024-12-19	Yale University	Methods and compositions for treating respiratory disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5968778A (en)	1989-01-12	1999-10-19	Jurgen Hoppe	PDGF-AB, preparation process and pharmaceuticals containing them
US5194596A (en) *	1989-07-27	1993-03-16	California Biotechnology Inc.	Production of vascular endothelial cell growth factor
US6207454B1 (en) *	1989-10-16	2001-03-27	Amgen Inc.	Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5476839A (en) *	1990-07-10	1995-12-19	Incyte Pharmaceuticals, Inc.	Basophil granule proteins
JP3024311B2 (ja)	1991-10-03	2000-03-21	味の素株式会社	Ｉｌ−２受容体重鎖に結合するポリペプチド
JPH05271294A (ja)	1992-01-24	1993-10-19	Japan Found Cancer Res	ヒトプロヒビチンおよびそれをコードするｄｎａ
WO1994002511A1 (en)	1992-07-27	1994-02-03	Pfizer Inc.	Calcium channel blocking polypeptide from agelenopsis aperta
US5510239A (en) *	1993-10-18	1996-04-23	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of multidrug resistance-associated protein
AU696764B2 (en)	1994-03-08	1998-09-17	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
DE4423098A1 (de)	1994-07-01	1996-01-04	Hoechst Ag	Verwendung von Pyrimidingruppen enthaltenden konjugierten Verbindungen als Elektrolumineszenzmaterialien
US5814464A (en)	1994-10-07	1998-09-29	Regeneron Pharma	Nucleic acids encoding TIE-2 ligand-2
US6645933B1 (en) *	1995-08-01	2003-11-11	Helsinki University Licensing Ltd. Oy	Receptor ligand VEGF-C
US6221839B1 (en) *	1994-11-14	2001-04-24	Helsinki University Licensing Ltd. Oy	FIt4 ligand and methods of use
JPH08185216A (ja)	1994-12-28	1996-07-16	Meidensha Corp	工具姿勢パラメータ設定方法及びロボット制御装置
US5928939A (en)	1995-03-01	1999-07-27	Ludwig Institute For Cancer Research	Vascular endothelial growth factor-b and dna coding therefor
CN1194090C (zh)	1995-03-02	2005-03-23	阿穆拉德业务有限公司	一种新的生长因子和编码这种生长因子的基因序列
WO1996039421A1 (en)	1995-06-06	1996-12-12	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 3
AU710696C (en) *	1995-09-08	2002-10-24	Genentech Inc.	VEGF-related protein
EP0853668B2 (en)	1995-09-29	2013-03-06	Vegenics Pty Ltd	Regulated genes and uses thereof
JP3843488B2 (ja)	1996-06-06	2006-11-08	アイシン・エィ・ダブリュ株式会社	自動変速機の制御装置
EP0935001B2 (en)	1996-07-15	2011-08-10	Chugai Seiyaku Kabushiki Kaisha	Novel vegf-like factors
DK0956339T3 (da)	1996-08-23	2006-01-30	Licentia Oy	Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
WO1998024811A2 (en)	1996-12-06	1998-06-11	Zymogenetics, Inc.	Vascular endothelial growth factor
US20020165174A1 (en) *	1997-01-31	2002-11-07	Gill Parkash S.	Methods and compositions for antisense VEGF oligonucleotides
US7947472B2 (en)	1997-12-24	2011-05-24	Vegenics Limited	Expression vectors and cell lines expressing vascular endothelial growth factor D
DE19817835C2 (de)	1998-04-22	2000-05-18	Billhofer Maschf Gmbh	Sichtkaschiervorrichtung
DE19823359C1 (de)	1998-05-15	1999-10-07	Francotyp Postalia Gmbh	Vorrichtung zum Bedrucken von Postgut
ATE322909T1 (de) *	1998-12-21	2006-04-15	Ludwig Inst Cancer Res	Antikörper gegen verkürzten vegf-d und deren verwendungen
CA2381985A1 (en) *	1999-08-16	2001-02-22	Universita'degli Studi Di Siena	Vegf-d and angiogenic use thereof
EP1635860A2 (en)	2003-06-12	2006-03-22	Ludwig Institute For Cancer Research	Use of vegf-c or vegf-d in reconstructive surgery
US20070212390A1 (en)	2005-09-22	2007-09-13	Ludwig Institute For Cancer Research	Protease-resistant forms of VEGF-D, method of making and method of use
FR2987282B1 (fr)	2012-02-24	2017-12-29	Fonds De L'espci Georges Charpak	Microcanal avec dispositif d'ouverture et/ou fermeture et/ou pompage
US9405291B2 (en)	2012-07-31	2016-08-02	Fisher-Rosemount Systems, Inc.	Systems and methods to monitor an asset in an operating process unit
US9516755B2 (en)	2012-12-28	2016-12-06	Intel Corporation	Multi-channel memory module
US9426605B2 (en)	2013-10-10	2016-08-23	Yahoo! Inc.	Cross device information exchange using gestures and locations

1997
- 1997-08-21 DK DK97938486T patent/DK0956339T3/da active
- 1997-08-21 ES ES09162873T patent/ES2390107T3/es not_active Expired - Lifetime
- 1997-08-21 ES ES97938486T patent/ES2251740T3/es not_active Expired - Lifetime
- 1997-08-21 WO PCT/US1997/014696 patent/WO1998007832A1/en active IP Right Grant
- 1997-08-21 DK DK09162873.5T patent/DK2107109T3/da active
- 1997-08-21 DK DK06121918T patent/DK1749836T3/da active
- 1997-08-21 DE DE69739469T patent/DE69739469D1/de not_active Expired - Lifetime
- 1997-08-21 ES ES06121918T patent/ES2327440T3/es not_active Expired - Lifetime
- 1997-08-21 JP JP51095398A patent/JP2001517075A/ja active Pending
- 1997-08-21 EP EP09162873A patent/EP2107109B1/en not_active Expired - Lifetime
- 1997-08-21 AT AT06121918T patent/ATE434034T1/de not_active IP Right Cessation
- 1997-08-21 EP EP06121918A patent/EP1749836B1/en not_active Expired - Lifetime
- 1997-08-21 US US08/915,795 patent/US6235713B1/en not_active Expired - Fee Related
- 1997-08-21 DE DE69734359T patent/DE69734359T2/de not_active Expired - Lifetime
- 1997-08-21 EP EP97938486A patent/EP0956339B1/en not_active Revoked
- 1997-08-21 AT AT97938486T patent/ATE306546T1/de not_active IP Right Cessation
- 1997-08-21 AU AU40796/97A patent/AU729880C/en not_active Ceased
- 1997-08-21 CA CA2263890A patent/CA2263890C/en not_active Expired - Fee Related
- 1997-08-21 EP EP02018842A patent/EP1283268A3/en not_active Withdrawn
1999
- 1999-04-22 US US09/296,275 patent/US6689580B1/en not_active Expired - Fee Related
2002
- 2002-06-05 US US10/161,694 patent/US7410639B2/en not_active Expired - Fee Related
- 2002-10-22 US US10/274,953 patent/US7122654B2/en not_active Expired - Fee Related
2003
- 2003-11-12 US US10/705,476 patent/US20040175730A1/en not_active Abandoned
2005
- 2005-12-16 US US11/304,585 patent/US20060177428A1/en not_active Abandoned
2007
- 2007-01-24 JP JP2007013569A patent/JP2007167072A/ja active Pending
- 2007-03-28 US US11/692,753 patent/US20080145366A1/en not_active Abandoned
- 2007-06-29 US US11/772,089 patent/US7662932B2/en not_active Expired - Fee Related
- 2007-08-23 US US11/843,867 patent/US7871798B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,120 patent/US7928061B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,537 patent/US7785803B2/en not_active Expired - Fee Related
2009
- 2009-07-10 JP JP2009164162A patent/JP2009291198A/ja active Pending
2011
- 2011-03-16 US US13/049,308 patent/US8227410B2/en not_active Expired - Fee Related
2012
- 2012-05-17 US US13/474,273 patent/US8445234B2/en not_active Expired - Fee Related
2013
- 2013-04-19 US US13/866,266 patent/US8759286B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20060177428A1 (en)	2006-08-10
AU729880B2 (en)	2001-02-15
JP2009291198A (ja)	2009-12-17
CA2263890C (en)	2013-05-14
US7410639B2 (en)	2008-08-12
US8445234B2 (en)	2013-05-21
US7122654B2 (en)	2006-10-17
EP1749836B1 (en)	2009-06-17
US20080145366A1 (en)	2008-06-19
AU729880C (en)	2001-11-08
US20090087905A1 (en)	2009-04-02
DE69739469D1 (de)	2009-07-30
EP2107109B1 (en)	2012-06-20
EP2107109A1 (en)	2009-10-07
US8227410B2 (en)	2012-07-24
US20030125537A1 (en)	2003-07-03
AU4079697A (en)	1998-03-06
ES2390107T3 (es)	2012-11-06
EP1749836A2 (en)	2007-02-07
US20080058258A1 (en)	2008-03-06
EP0956339A1 (en)	1999-11-17
ES2327440T3 (es)	2009-10-29
EP1283268A2 (en)	2003-02-12
US20080070831A1 (en)	2008-03-20
US7871798B2 (en)	2011-01-18
ATE434034T1 (de)	2009-07-15
US20110281799A1 (en)	2011-11-17
HK1025789A1 (en)	2000-11-24
US7928061B2 (en)	2011-04-19
US20070298493A1 (en)	2007-12-27
EP1283268A3 (en)	2004-01-02
US20130345409A1 (en)	2013-12-26
US7662932B2 (en)	2010-02-16
US20040175730A1 (en)	2004-09-09
ATE306546T1 (de)	2005-10-15
CA2263890A1 (en)	1998-02-26
US20120322105A1 (en)	2012-12-20
WO1998007832A1 (en)	1998-02-26
DK0956339T3 (da)	2006-01-30
US6235713B1 (en)	2001-05-22
DK2107109T3 (da)	2012-09-24
DE69734359T2 (de)	2006-07-06
EP0956339B1 (en)	2005-10-12
US20030114658A1 (en)	2003-06-19
JP2007167072A (ja)	2007-07-05
US6689580B1 (en)	2004-02-10
US8759286B2 (en)	2014-06-24
US7785803B2 (en)	2010-08-31
JP2001517075A (ja)	2001-10-02
EP0956339A4 (en)	2000-08-23
DE69734359D1 (de)	2006-02-23
ES2251740T3 (es)	2006-05-01
EP1749836A3 (en)	2007-08-22

Publication	Publication Date	Title
DK1749836T3 (da)	2009-08-31	Rekombinant vaskulær endothelcellevækstfaktor D
NO973933D0 (no)	1997-08-27	Vaskulær endotelvekstfaktor B
ATE556090T1 (de)	2012-05-15	Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung
ATE110108T1 (de)	1994-09-15	Genetische modifizierung von endothelialen zellen.
DE69434538D1 (de)	2005-12-15	Vaskularer endothelialer wachstumsfaktor 2
DE69033710D1 (de)	2001-04-12	Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
EP2039769A3 (en)	2009-06-17	Antimicrobial peptides and methods of use
ATE121781T1 (de)	1995-05-15	Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions- kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
ATE114169T1 (de)	1994-12-15	Morphogenetisches knochenprotein.
ES2141761T3 (es)	2000-04-01	Secuencias de dna codificantes de nuevos factores de crecimiento/diferenciacion.
WO1995005452A3 (en)	1995-03-30	Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
AU2001254624A1 (en)	2001-11-12	Human coagulation factor vii variants
DE69434332D1 (de)	2005-05-19	Thrombin mutanten
DE3580283D1 (de)	1990-12-06	Biologisch wirksame substanz mit hormonellen eigenschaften, verfahren zu ihrer herstellung und verwendung von histonen fuer medizinische zwecke.
IL70776A (en)	1991-09-16	Recombinant dna molecule encoding at least one polypeptide displaying the immunogenicity of at least one merozoite antigen or asexual blood stage antigen of p.falciparum,vectors comprising the dna molecule,host cells transformed thereby,immunogenic polypeptides produced by host cells and compositions containing the polypeptides
NO892033D0 (no)	1989-05-19	Fibronectinbindende protein.
ATE121776T1 (de)	1995-05-15	Expression des biologisch aktiven faktors xiii.
SE8902507L (sv)	1989-07-11	Neutrofil-aktiverande faktor
WO2002050111A3 (en)	2002-09-12	Isolated laminin 10
DE60042793D1 (de)	2009-10-01	Inhibitor des hepatozytwachstumsfaktoraktivators und dessen verwendung zur modulation von angiogenese und herzvaskularisierung
DK0939769T3 (da)	2006-03-13	Vertebrat-Smoothened-proteiner
EP0676413A3 (en)	1996-04-03	Interferon alpha / beta binding protein, its production and application.
WO2001053324A8 (en)	2002-10-10	Novel haptotactic peptides
WO2002059618A3 (en)	2003-05-08	Growth factor polypeptides and nucleic acids encoding same
ATE105335T1 (de)	1994-05-15	Traegergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.